Xiaozhen Cai, Jian-hua Huang, Hai-Huan Zeng, Xuejuan Wang
{"title":"Role of autophagic response in glutamine treatment attenuating inflammation in rats after traumatic brain injury","authors":"Xiaozhen Cai, Jian-hua Huang, Hai-Huan Zeng, Xuejuan Wang","doi":"10.3760/CMA.J.ISSN.1674-635X.2018.02.007","DOIUrl":null,"url":null,"abstract":"Objective \nTo investigate the effect of glutamine (GLN) treatment on neurobehavioral outcome, brain edema and inflammatory response in rats after traumatic brain injury (TBI), and to find out the role played by autophagic response in this effect. \n \n \nMethods \nRat models with TBI in this study were established using Feeney's method. One hundred healthy male SD rats were randomly divided into five groups (n=20) to receive sham operation (group Sham), TBI (group TBI), TBI and glutamine treatment (group TBI+ GLN), TBI amd autophagy inhibitor 3-methyladenine (group TBI+ 3-MA), and TBI, GLN and autophagy inhibitor (group TBI+ GLN+ 3-MA). We measured the rats' behavioral outcomes by modified neurologic severity score (mNSS) tests at day 1, 3, 7 and 14 after intervention. Brain water content was measured with wet-dry weight method. The serum levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1 and IL-4 were tested using enzyme linked immunosorbent assay. The expressions of autophagy-related factors (LC3-Ⅱ, Beclin-1) in TBI cerebral cortex were tested with Western blot. \n \n \nResults \nCompared with the Sham group, the other four groups had significantly increased levels of brain edema, mNSS, serum inflammatory factors and cerebral LC3-Ⅱ and Beclin-1 (P=0.00). Compared with the TBI group, the TBI+ GLN group had less severe brain edema and improved mNSS, lower levels of TNF-α [(57.71±9.69)pg/ml vs. (83.37±12.81)pg/ml, P=0.01] and IL-1 [(39.46±8.60)pg/ml vs. (69.04±10.48)pg/ml, P=0.00], higher levels of IL-4 [(68.72±11.18)pg/ml vs. (35.75±8.40)pg/ml, P=0.04], and upregulated expressions of LC3-Ⅱ and Beclin-1 (P=0.01). Compared with the TBI+ GLN group, the TBI+ GLN+ 3-MA group had severer neurofunctional impairment, brain edema and inflammation (P<0.05). \n \n \nConclusions \nTreatment with GLN markedly reduced brain edema and improved neurobehavioral outcomes in rats with TBI by inhibiting inflammatory response in the central nervous system. The mechanism might have been the activation of the autophagic response. \n \n \nKey words: \nTraumatic brain injury; Glutamine; Inflammation; Autophagy; Neuroprotection","PeriodicalId":9877,"journal":{"name":"中华临床营养杂志","volume":"26 1","pages":"100-105"},"PeriodicalIF":0.0000,"publicationDate":"2018-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华临床营养杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1674-635X.2018.02.007","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Nursing","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
To investigate the effect of glutamine (GLN) treatment on neurobehavioral outcome, brain edema and inflammatory response in rats after traumatic brain injury (TBI), and to find out the role played by autophagic response in this effect.
Methods
Rat models with TBI in this study were established using Feeney's method. One hundred healthy male SD rats were randomly divided into five groups (n=20) to receive sham operation (group Sham), TBI (group TBI), TBI and glutamine treatment (group TBI+ GLN), TBI amd autophagy inhibitor 3-methyladenine (group TBI+ 3-MA), and TBI, GLN and autophagy inhibitor (group TBI+ GLN+ 3-MA). We measured the rats' behavioral outcomes by modified neurologic severity score (mNSS) tests at day 1, 3, 7 and 14 after intervention. Brain water content was measured with wet-dry weight method. The serum levels of tumor necrosis factor-α (TNF-α), interleukin (IL)-1 and IL-4 were tested using enzyme linked immunosorbent assay. The expressions of autophagy-related factors (LC3-Ⅱ, Beclin-1) in TBI cerebral cortex were tested with Western blot.
Results
Compared with the Sham group, the other four groups had significantly increased levels of brain edema, mNSS, serum inflammatory factors and cerebral LC3-Ⅱ and Beclin-1 (P=0.00). Compared with the TBI group, the TBI+ GLN group had less severe brain edema and improved mNSS, lower levels of TNF-α [(57.71±9.69)pg/ml vs. (83.37±12.81)pg/ml, P=0.01] and IL-1 [(39.46±8.60)pg/ml vs. (69.04±10.48)pg/ml, P=0.00], higher levels of IL-4 [(68.72±11.18)pg/ml vs. (35.75±8.40)pg/ml, P=0.04], and upregulated expressions of LC3-Ⅱ and Beclin-1 (P=0.01). Compared with the TBI+ GLN group, the TBI+ GLN+ 3-MA group had severer neurofunctional impairment, brain edema and inflammation (P<0.05).
Conclusions
Treatment with GLN markedly reduced brain edema and improved neurobehavioral outcomes in rats with TBI by inhibiting inflammatory response in the central nervous system. The mechanism might have been the activation of the autophagic response.
Key words:
Traumatic brain injury; Glutamine; Inflammation; Autophagy; Neuroprotection
期刊介绍:
The Chinese Journal of Clinical Nutrition was founded in 1993. It is the first professional academic journal (bimonthly) in my country co-sponsored by the Chinese Medical Association and the Chinese Academy of Medical Sciences to disseminate information on clinical nutrition support, nutrient metabolism, the impact of nutrition support on outcomes and "cost-effectiveness", as well as translational medicine and nutrition research. It is also a professional journal of the Chinese Medical Association's Parenteral and Enteral Nutrition Branch.
The purpose of the Chinese Journal of Clinical Nutrition is to promote the rapid dissemination of knowledge on nutrient metabolism and the rational application of parenteral and enteral nutrition, focusing on the combination of multidisciplinary and multi-regional field investigations and clinical research. It mainly reports on nutritional risk screening related to the indications of parenteral and enteral nutrition support, "cost-effectiveness" research on nutritional drugs, consensus on clinical nutrition, guidelines, expert reviews, randomized controlled studies, cohort studies, glycoprotein and other nutrient metabolism research, systematic evaluation of clinical research, evidence-based case reports, special reviews, case reports and clinical experience exchanges, etc., and has a special column on new technologies related to the field of clinical nutrition and their clinical applications.